Search

Displaying results 851 - 860 of 7554 in total
  1. Drug

    Gemtuzumab ozogamicin

    go.drugbank.com/drugs/DB00056
    ApprovedInvestigational

    On September 1 2017, gemtuzumab ozogamicin was again approved for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia but with a lower dosing regimen and a different schedule … By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death.

  2. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [A189207,A189213] Previous agents within this class were efficacious but limited by liver toxicity - this led to the development of ubrogepant, which was designed to be a hepatoxicity-free alternative … [L10959] Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and [rimegepant]

  3. Drug

    Sulopenem etzadroxil

    go.drugbank.com/drugs/DB16335
    ApprovedInvestigational

    [L51768] Sulopenem etzadroxil was approved by the FDA in October 2024 for the treatment of uncomplicated urinary tract infections. … [L51858] It is administered in combination with [probenecid] in order to increase antibiotic exposure.[L51768]

  4. Drug

    Pemetrexed

    go.drugbank.com/drugs/DB00642
    ApprovedInvestigational

    Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.[A253907] … Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta.

  5. Drug

    Estradiol acetate

    go.drugbank.com/drugs/DB13952
    ApprovedVet approved

    However, after menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. … First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102].

  6. Drug

    Reviparin

    go.drugbank.com/drugs/DB09259
    Approved

    [A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469] … Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin.

  7. Drug

    Cefamandole

    go.drugbank.com/drugs/DB01326
    ApprovedWithdrawn

    It is no longer marketed in the United States.

  8. Drug

    Isosorbide

    go.drugbank.com/drugs/DB09401
    ApprovedInvestigational

    It was approved by the FDA in 1980, but has since been discontinued. … Refer to these drug entries for more information.

  9. Drug

    Repaglinide

    go.drugbank.com/drugs/DB00912
    ApprovedInvestigational

    The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. … It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release.

  10. Drug

    Clarithromycin

    go.drugbank.com/drugs/DB01211
    ApprovedInvestigational

    Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. … Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.

    Synonyms: 6-O-methyl erythromycin, 6-O-methylerythromycinProducts: KLACID UNO, Clarithromycin Uno STADA 500 mg Retard-Filmtabletten